CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers | GenomeWeb

 

NEW YORK (GenomeWeb) – The Cancer Research UK Manchester Institute announced today it has joined Cancer-ID, a European consortium to validate blood-based biomarkers for cancer. 

With a total budget of €14.5 million ($15.7 million), Cancer-ID is a newly created consortium funded by the Innovative Medicines Initiative. It currently has 33 members from 13 countries tasked with establishing standard protocols for and clinical validation of blood-based biomarkers, such as circulating tumor cells, cell-free tumor DNA, and microRNAs. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.